How is Neulasta® typically given (administered)?
Neulasta® is given as a subcutaneous (under the skin) injection and comes in prefilled syringes. The recommended dose of Neulasta® is a prefilled syringe (6 mg) once per chemotherapy cycle. Neulasta® should not be given to infants, children, or adolescents weighing less than 45 kilograms. How are patients typically monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Neulasta®. Typically, blood will be drawn to check levels of white blood cells. Patients may also undergo physical examinations, scans or other measures to assess side effects and response to therapy. What are the common (occur in 30% or more of patients) side effects of treatment with Neulasta®? There are no known common side effects attributable to Neulasta®. What are the less common (occur in 10% to 29% of patients) side effects of treatment with Neulasta®? • Bone pain • Changes in some laboratory tests, which tend to normalize following treatment • So
